The primary purpose is to review guidance on the testing and treatment of latent tuberculosis infection (LTBI) in children. Most children and adults with LTBI have positive tuberculin skin test (TST) or interferon gamma release assay (IGRA) results, normal examinations, and normal chest radiographs. Diagnosis of and treatment completion for LTBI are critical to diminish future cases of tuberculosis (TB) disease.
INTRODUCTION
Children comprise a minority of tuberculosis (TB) patients [1] . The risk of progression from latent tuberculosis infection (LTBI) to TB disease is greatest in infants, decreases when children are 5-10 years of age, and increases during adolescence [2, 3] . The probability of TB disease developing can be reduced substantially with treatment. In the United States, the majority of pediatric TB cases are attributable to healthcare providers missing opportunities for prevention [4 && ,5] . Missed opportunities include not testing children with TB risk factors for LTBI and not initiating or completing treatment in children who are diagnosed with LTBI. Diagnosis of and treatment completion for LTBI are essential components of the strategy to eliminate TB [6] .
This review is intended to update general practitioners, including primary care pediatricians, on the fundamentals of preventing TB by diagnosing and treating LTBI. It will consider risk factors for LTBI; new options for LTBI diagnosis; new treatment regimens for preventing TB disease; frequency of, and monitoring for, adverse events; barriers to treatment initiation and completion; and strategies to increase adherence with LTBI therapy. Treatment of HIV-infected children with LTBI and of children infected after contact with persons with multidrugresistant (MDR)-TB will not be discussed in detail because it is recommended that their management Associations with infection by Mycobacterium tuberculosis are well established [2] . Testing children who are unlikely to be infected gives poor predictive value of positive results. Thus, the American Academy of Pediatrics (AAP) does not recommend universal testing for LTBI. The dominant factors associated with LTBI among children in the United States are birth in or travel to a high-incidence country and being a contact of a household member with a history of LTBI or TB disease [7] . A simple screening tool incorporating these questions has been validated for LTBI screening in diverse community settings [8, 9] . As the number of risks present increases, the tool becomes more specific and the positive predictive value of test results increases. Children with at least one factor associated with LTBI should be tested. However, one study indicated that a minority of pediatric providers use a standardized questionnaire among school-aged children [10] . More recently, association with parental birth abroad was reported for US-born children with TB [4 && ]. This characteristic has yet to be prospectively validated, and is not usually included in screening questionnaires.
It is important to distinguish which children with LTBI have a high risk of progressing to TB disease. In contrast to the epidemiologic risk factors for acquisition of infection, the factors related to progression to disease are primarily associated with immunologic status: age younger than 5 years, M. tuberculosis infection within the past 2 years, and those factors also affecting adults, for example, HIV infection or other immunocompromising conditions or receipt of immunosuppressive medications [7] .
OPTIONS FOR LATENT TUBERCULOSIS INFECTION TESTING
Two options exist for the diagnosis of LTBI: the tuberculin skin test (TST) and IGRAs (Table 1) 12] . No reference standard currently exists for LTBI diagnosis, and, therefore, the pretest probability of infection and studies in children who have TB disease are used for estimating the sensitivity of these tests for LTBI and their predictive values [13 && ]. TSTs are interpreted according to the individual's risk profile. The amount of induration in millimeters considered positive optimizes sensitivity for children at highest risk of progression to TB disease and improves specificity for children who are less likely to have been infected (Table 1) [13 && ]. In a low-risk population, the vast majority of positive TSTs in children without a risk factor will be false-positive results, emphasizing the need to focus LTBI screening on those with an associated factor for LTBI in order to lessen unnecessary tests and treatment. For these reasons, policies that promote universal testing of persons (e.g., all children entering school) without a factor associated with infection should be discouraged.
IGRAs are blood tests that detect interferon gamma released by lymphocytes ex vivo after stimulation with overlapping peptide sequences that simulate M. tuberculosis-specific antigens. These peptide sequences have antigenic homology with three nontuberculous pathogenic mycobacterial species -M. kansasii, M. marinum, and M. szulgaibut the clinical significance of the potential crossreaction has not been determined. IGRAs offer several advantages over the TST, including superior specificity for patients who are sensitized to purified protein derivative tuberculin antigens because of bacille Calmette-Guérin (BCG) vaccination or infection with a nontuberculous mycobacterium, for example, M. avium; a single definition for test positivity, and the need for only one healthcare encounter. Situations in which IGRAs are the preferred test for diagnosing LTBI in children are summarized in Table 2 
KEY POINTS
Use of a standardized questionnaire to select children for testing based on assessment of established factors associated with TB focuses on children with the highest risk for having LTBI and possible progression to TB disease.
Use of IGRAs, with their improved specificity particularly for children who have received the BCG vaccine, may decrease the number of uninfected children receiving therapy and enable limited resources to be focused on children who would benefit the most from therapy.
Multiple LTBI treatment regimens have been studied to varying degrees: selection of regimen should take efficacy, adherence, family preference, possible sideeffects, cost, and availability of DOT into consideration.
Children at the highest risk for progression to TB disease should be considered candidates for DOT to optimize adherence. For children for whom DOT is unavailable, adherence may be increased by incentives and enablers.
IGRAs may be of particular use is BCG-vaccinated children. The current generation of IGRAs was designed to take advantage of antigens that are present in M. tuberculosis complex, including wildtype M. bovis, but absent in BCG, which is prepared from attenuated strains of M. bovis. BCG vaccination diminishes TST specificity because of cross-reactive antigens, with complex interactions between the age at vaccination, the interval between vaccination and TST, the number of BCG doses, and the timing between TSTs (i.e., the skin test 'boosting' phenomenon) [15, 16] . In studies to date, BCG vaccination has not been found to influence IGRA results.
Two commercial IGRA testing systems, Quanti-FERON-TB Gold (Qiagen) and T-SPOT.TB (Oxford Immunotec) are licensed by the US Food and Drug Administration for sale. Neither Centers for Disease Control and Prevention (CDC) nor the AAP recommends one IGRA over another [13 && ,14] . IGRA incorporation into existing screening protocols in pediatric offices has been limited by insufficient data available in preschool-aged children, by the need for venipuncture and training on specimen handling, and by the incomplete market penetration of IGRAs. Another limiting factor is that indeterminate results for IGRA of up to 24% have been reported in children less than 5 years of age [17, 18] , reducing its utility as a diagnostic test in this population.
Focused testing of individuals with a risk for infection with M. tuberculosis is a more cost-effective strategy than universal screening; however, there is 
TREATMENT REGIMENS
Children with positive TST or IGRA results must be evaluated for TB disease prior to initiation of treatment for LTBI. The evaluation should include a CXR and a thorough physical examination, with particular attention to peripheral lymphadenopathy, and possibly collection of specimens for acid-fast bacillus staining, mycobacterial culture, and drug susceptibility testing. If TB disease is suspected or the primary care physician cannot manage LTBI diagnosis and treatment, the child should be referred to the health department or a pediatrician familiar with TB, for evaluation and treatment.
Once TB disease has been excluded, the provider can discuss LTBI treatment options with the family. Historically, the approach to LTBI therapy in the United States has been monolithic, relying upon isoniazid (isonicotinylhydrazine, INH) in all but a few select clinical situations. Data supporting nonisoniazid-based regimens have largely been derived from studies in adults. The decision as to which regimen to use should take adherence, drug susceptibility results of the presumed source case (if known), safety, cost, and patient preference into consideration [2] . Children at high risk of TB disease may be candidates for directly observed therapy (DOT), in which a healthcare worker or other trained person watches a patient swallow each dose of medication. DOT is one of the few interventions to be associated with improved treatment adherence [20] . In Houston, twice weekly LTBI therapy via DOT was shown to be effective in a cohort of over 400 children [21] . Other effective strategies include calendars for parental monitoring, treatment with incentives in the form of small toys or books provided to the child [22] , school-based DOT [23] , and adherence coaching for adolescents [24] .
The current standard of practice in the United States for treating LTBI is 9 months of daily INH, unless documented resistance to INH is shown in the source case. INH is bactericidal and it is highly efficacious if taken as indicated. The chief problem with this regimen is that adherence with a 9-month regimen is poorer than with shorter regimens, limiting effectiveness.
A 4-month course of rifampin has been shown to be less costly, better tolerated, and more likely to be completed in adults than 9 months of INH [25] ; the current AAP recommendation is a 6-month course [14] , but no study has ever used this regimen. A course of treatment using rifampin is recommended when the child is known to be exposed to an infectious person with an INH-resistant strain or is intolerant to INH [14] . Rifampin is well tolerated by children [26] , and the 4-month course probably will result in improved adherence but needs further study. A shorter course regimen, a 3-month combination of daily INH and rifampin, has been shown to be successful in children and associated with good adherence in the United Kingdom [27] , although this regimen has not been included in guidelines for the United States. Rifapentine, a longer-acting rifamycin, can be administered once weekly in combination with INH. A recent landmark study indicated that 12 weekly doses of INH and rifapentine was noninferior to 9 months of INH in persons at least 12 years of age and had higher completion rates [28 && ]. This is now a CDC-recommended regimen [29] . As with all intermittent dosing of TB medication (intermittent dosing can be once, twice or thrice weekly), this combination therapy is recommended only via DOT, as even one missed dose results in an almost 10% dose reduction. Follow-up of a cohort of younger children (2-11 years old) is ongoing. To date, this regimen also appears to be well tolerated and safe in this age group [30] .
For children less than 12 years of age, the preferred regimen remains 9 months of INH until further data and experience are available. However, certain scenarios may warrant the use of 4 months of daily rifampin or 3 months of weekly INH/rifa pentine. These situations are discussed in Table 3 [14,31]. For adolescents, 3 months of weekly INH/rifapentine given by DOT may be considered, especially when adherence is questionable. For families who can afford the cost of rifampin (or for regions where LTBI therapy is provided free to children), 4 months of rifampin may be the next best alternative to 9 months of INH for school-aged children and adolescents for whom INH/rifapentine is not available.
One important scenario relates to children with LTBI for whom immunosuppressive therapy [e.g., tumor necrosis factor-a (TNF-a) antagonists] has been or will be initiated by the child's specialist. Although it is optimal to complete as much of the LTBI course as possible prior to the child becoming immunosuppressed, this is not always possible. At a minimum, expert opinion for the treatment of adults is that 4 weeks of LTBI therapy should be taken prior to initiating immunosuppression. This is a circumstance under which shorter course regimens would be preferable, so that a larger percentage of therapy can be completed prior to initiation of immunosuppression. However, clinicians must first be sure that the rifampin or rifapentine does not interact with any other medications, because rifamycins are potent inducers of cytochrome P450 enzymes that catalyze the oxidation of other drugs. 
ADVERSE DRUG EVENTS
Most children tolerate TB medications far better than adults, and serious adverse events are rare [2] . Consequently, baseline and serial laboratory evaluation are unnecessary for the otherwise healthy child who is not receiving other potentially hepatotoxic medications. Asymptomatic increases of serum transaminase concentrations (two to three times the upper limit of normal) are common in children and have no clinical significance; thus, routine measurement of transaminase concentrations may result in further unnecessary testing, unnecessary treatment interruptions, or cessation of therapy if mild increases are noted. Measuring baseline serum transaminase concentrations is reasonable for children and adolescents having HIV infection, receiving medications that may potentially interact with TB medication, having underlying or recent hepatic or biliary disease, or being pregnant or in the first 6 weeks postpartum. Children should be followed up regularly by providers. Although monthly visits are strongly preferred and recommended, this may not be feasible for some families. At all visits, parents should be given written instructions and informed of possible adverse events so that they will know to stop administering medications if such events are observed. Lack of parental education about adverse events and failure to seek timely care might contribute to severe hepatotoxicity and other adverse drug effects [32] . In consideration of drug-induced liver injury, it is reasonable to interrupt the treatment regimen and promptly evaluate a child (by physical examination and laboratory evaluation) who has anorexia, nausea and vomiting, or abdominal pain. Signs and symptoms of hepatic toxicity should prompt immediate medication cessation with thorough relevant laboratory testing, including hepatic transaminases and bilirubin (conjugated and unconjugated). For children with a serum transaminase concentration, with or without symptoms, great enough to warrant stopping treatment or hyperbilirubinemia, additional testing should be done in consultation with an expert in pediatric TB. In addition, tests for agents causing viral hepatitis should be obtained because these pathogens remain a common cause of hepatic dysfunction.
Suspected drug-associated urticaria or more severe systemic reactions should prompt immediate cessation of the drug(s) and change to a different regimen after symptom improvement. A history of exposure to other medications, new foods, detergents, soaps, and skin lotions should be obtained. In children receiving other medications, clinicians should verify that the selected LTBI regimen will not result in major drug-drug interactions. Isoniazid is known to possibly affect anticoagulant agents, some anticonvulsants, benzodiazepines, and other classes of drugs. Rifampin interacts with multiple classes of drugs, including several antiepileptics, antifungals, antiretrovirals, hormonal contraceptives (e.g., birth control pills), and immunosuppressants.
BARRIERS TO COMPLETION OF THERAPY AND STRATEGIES FOR IMPROVING ADHERENCE
At least one-half of children who begin LTBI therapy with the 9-month INH regimen successfully complete treatment [20, 33] . Most treatment default occurs in the first couple of months. There have been several studies attempting to outline characteristics of families of children who complete and those who fail to initiate or complete LTBI treatment. Adherence has been associated with greater TB knowledge, convenient appointment times [34] , having a medical home [35] , being of African or Latin American origin [33] , self-selection of the treatment regimen, and promptly seeing a provider after having a positive TST result [23] . Nonadherence was associated with believing that taking medication would be challenging, and with having been previously recommended for LTBI treatment, and was more common in children of families from eastern Europe and Asia [33] . A recent study found that the only factor associated with successful completion of LTBI treatment was administration of medications by local health departments through DOT [20] . In this study, completion of therapy was approximately 50% when families administered medication, in contrast to greater than 95% when workers from the health department administered medication via DOT.
A less resource-intense alternative to DOT is enhanced self-administered therapy (ESAT). ESAT programs provide medication to families monthly, with periodic phone calls to remind families about adherence and to ask about adverse events. The rate of completion of LTBI therapy using INH was 86% using ESAT in one cohort [20] .
To improve treatment completion, practitioners need to routinely use measures to enhance adherence. Some measures may be best carried out in partnership with local health departments. Children at high risk for progression to disease are candidates for DOT. However, DOT is a limited resource in many settings. Other strategies to increase familial adherence are listed in Table 4 . Administration of LTBI therapy through schoolbased clinics [23] or through extended-hour community-based clinics [35] has been shown to improve completion of therapy. From a practical standpoint, if a child completes at least 6 months of isoniazid before defaulting, therapy may be considered completed, as it is unlikely the family will be interested in restarting a course of therapy, and a 6-month course of daily INH is known to have intermediate efficacy, at least for adults [36] . However, if INH is chosen, 9 months of therapy should be the goal.
CONCLUSION
There are two modalities for diagnosing LTBI, as well as several effective treatment regimens, which can be used for infected children. The first step in screening children and adolescents is a risk factor assessment. Diagnostic tests should optimize sensitivity in children at risk for rapid progression to disease (e.g., infants, recently infected, immunocompromised) and optimize specificity for children with fewer risk factors or vaccination with BCG, thereby decreasing the number of uninfected children receiving therapy. If LTBI is diagnosed, the decision as to which AAP/CDC-recommended regimen to use should consider adherence factors and factors that may limit the choice of medications. 
